8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

_____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  June 20, 2007

HUMAN PHEROMONE SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

CALIFORNIA	0-23544	94-3107202
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS  Employer Identification No.)
84 W. SANTA CLARA STREET, SUITE 720, SAN JOSE, CALIFORNIA    95113
Address of principal executive offices, including       zip code
Registrant’s telephone number, including area code: (408) 938-3030
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(B))

¨

Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4c))

ITEM 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 20, 2007, the Board of Directors of Human Pheromone Sciences, Inc. (the Registrant, the “Company” or “HPS”) elected Mr. Carson Tang as a director of the Company to serve until the Company’s 2008 meeting of shareholders.  Mr. Tang serves as the Managing Partner of the Renovatio Global Fund, a technology-based fund based in San Jose, California.  Renovatio Global Fund currently holds approximately 655,000 shares (16%) of the Company’s Common Stock.  Mr. Tang also was appointed a member of the Board’s compensation committee to fill the seat previously held by Mrs. Helen Leong, who will continue as the Audit Committee chairperson.

As a non-employee director of the company, Mr. Tang received an initial stock option grant of 20,000 shares of Common Stock, which will vest and become exercisable at the rate of one-twelfth of the number of shares covered by the option each month following the grant date, so long as Mr. Tang is serving as a director, with full vesting on June 20, 2008.  The option exercise price is $0.82 per share, which was the closing price of the Company’s common stock on the day of the grant. Mr. Tang will receive automatic annual option grants on the same terms as other non-employee directors.

ITEM 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

99.1

Press Release dated June 25, 2007.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMAN PHEROMONE SCIENCES, INC.

Date:  June 25, 2007

By: /s/ William P. Horgan                                   

William P. Horgan, Chief Executive Officer

- 3 -

EXHIBIT INDEX

99.1

Press Release dated June 25, 2007.

- 4 -

EX-99.1 CHARTER

Exhibit 99.1

For Further Information:

Human Pheromone Sciences, Inc.

84 West Santa Clara Street, Suite 720

San Jose, CA  95113

(408) 938-3030

Contact:  

William P. Horgan

Chairman, CEO

For Immediate Release

Human Pheromone Sciences Names Additional Director

San Jose, California, June 25, 2007.  Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX.OB) (“HPS” or “the Company”) announced today that Mr. Carson Tang was appointed to its Board of Directors.   

 Mr. Tang currently serves as Managing Partner to the Renovatio Global Fund, a technology-based fund based in San Jose, California.  He is active in investing in and managing enterprises in Greater China, including Taiwan, China and Singapore.

Renovatio Global Fund currently holds approximately 655,000 shares (16%) of the Company’s Common Stock.  In commenting on the appointment, a Company spokesperson indicated that “we are very pleased that Carson has agreed to join our Board; he brings a great deal of experience in financing and investing in technology–driven companies as well as a wealth of experience in dealing in the increasingly important Asian markets.”

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction®, REALM®, innerREALM® and  EROX® trademarks.  These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results.  Further information on factors that could affect the Company’s results is detailed in the Company’s annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-QSB for the quarter ended March 31, 2007,  as filed with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, except as required by law.

- 2 -